From Yahoo Finance: 2025-06-07 18:52:00

Hims & Hers is disrupting telemedicine with a 157% stock jump, but analysts are cautious due to high short interest. The company’s subscription model boasts 2.4 million users and $586 million revenue, focusing on AI investments for growth. Despite potential, Wall Street remains lukewarm, with a $48 price target and skepticism about volatility and long-term prospects.



Read more at Yahoo Finance: Is Hims & Hers Health a Smart Buy Right Now?